Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

with BioNTech/Pfizer and Moderna continuing to dominate the market. BioNTech's mRNA pipeline, which requires expertise in the modality as well as bioinformatics, will be difficult to replicate by ...

The British pharma giant alleges that Moderna ignored patents relating to lipid nanoparticles used in mRNA vaccine formulation technology. It follows a similar lawsuit against Pfizer and BioNTech ...

Moderna, along with rivals Pfizer and BioNTech, achieved an astonishing public health success by developing an mRNA vaccine to fight the COVID-19 pandemic in less than a year. The companies also ...

An abundance of evidence indicates the mRNA COVID-19 vaccines are remarkably safe and work well to protect against severe disease. But last month, the state of Florida issued updated vaccine guidance ...